Ryan Weight, DO
Hematology & Oncology · Aurora, CONPI 1346553591
Payments from drug & device makers
Across 1,491 payments — averaging $1973.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$2.4M
- E.r. Squibb & Sons, L.L.C.$266K
- Pfizer$134K
- Iovance Biotherapeutics, Inc.$88K
- Merck$62K
- Immunocore Limited$18K
- plus $17K from 14 others
Across 15 payments — averaging $405.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$6K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 1,340 | $2,358,027 |
| E.r. Squibb & Sons, L.L.C. | 17 | $266,009 |
| Pfizer | 6 | $133,576 |
| Iovance Biotherapeutics, Inc. | 14 | $88,475 |
| Merck | 24 | $62,309 |
| Immunocore Limited | 27 | $17,554 |
| Regeneron Healthcare Solutions, Inc. | 18 | $11,373 |
| Sanofi | 9 | $3,124 |
| Array Biopharma Inc | 8 | $1,394 |
| Delcath Systems | 2 | $270 |
| Bristol Myers Squibb | 5 | $150 |
| Novartis | 5 | $109 |
| Sun Pharmaceutical Industries Inc. | 5 | $101 |
| Merit Medical Systems Inc | 1 | $57 |
| Kyowa Kirin, Inc. | 2 | $52 |
| Tempus AI, Inc | 2 | $44 |
| Genentech USA, Inc. | 2 | $36 |
| Tactile Systems Technology Inc | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Blueprint Medicines Corporation | 1 | $16 |
How this compares
$2,942,729 in reported general payments places this provider in the 85th percentile of 169 hematology & oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Aurora
- John BurkeAurora$25.4M
- Elena ShagisultanovaAurora$22.4M
- Elaine LamAurora$12.6M
- Daniel PollyeaAurora$9.4M
- Manali KamdarAurora$8.9M
- Jennifer DiamondAurora$7.1M
- Thomas FlaigAurora$5.9M
- Sujatha NallapareddyAurora$1.7M
- Sami DiabAurora$1.6M
- Breelyn WilkyAurora$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.